These findings highlight the potential of <i>Nr4a1</i> as an immunotherapeutic target in T cell-mediated autoimmune arthritis, particularly in RA subsets characterized by TCR signaling dysfunction. The gene discussed is NR4A1; the disease is rheumatoid arthritis.